Skip to main content

A study from IRB Barcelona describes the reaction mechanism of DNAzymes and opens new propsects in the field of biocatalysers

Images

Participants

Contact

Image
Press & Communications Section Head
Tel.+34 93 40 37255

Modesto Orozco’s lab (IRB Barcelona) has published a study on the reaction mechanism of DNAzymes in Nature Catalysis.

DNAzymes, which are catalysers formed by DNA, have applications in biomedicine and biotechnology. These research results will contribute to advances in the design and improvement of catalysers for therapeutic purposes.

A study from the Institute for Research in Biomedicine (IRB Barcelona) has published a study in the journal Nature Catalysis that describes the reaction mechanism used by the DNAzyme 9DB1, the first structurally available catalyser formed by DNA.

Until recently, it was widely assumed that DNA served to store genetic information in a stable and irreversible manner. However, in the last ten years, the discovery of the epigenetic code and the finding that nucleic acids can also catalyse certain reactions have changed this vision. 

The team headed by Modesto Orozco, head of the Molecular Modelling and Bioinformatics Lab at IRB Barcelona, found that this DNAzyme catalyses RNA ligation through a similar mechanism to that used by natural enzymes.

The conclusion drawn by the study may lead to improvements in current catalysers and in the design of novel biocatalysers formed by DNA. Indeed, given that DNAzymes can carry out a variety of reactions on messenger RNA and can trigger the silencing of genes, they are being developed for diagnostic and biomedical applications. 

“The role of DNAzymes as catalysers is of great interest since they are easier to synthesise than proteins and RNA molecules, as well as being more stable and less expensive. However, to date, the catalytic mechanism used by DNAzymes was unknown, as were the differences between catalysers made of DNA and RNA or the protein enzymes,” says Orozco, senior professor at the University of Barcelona.

The study published by the IRB Barcelona team aimed to unravel the details of the catalytic mechanism of DNAzymes. To this end, Juan Aranda and Montserrat Terrazas, postdoctoral fellows at IRB Barcelona and first authors of the work, studied DNAzyme 9DB1 at the atomic level using computational simulations and then experimentally validated their findings.

The various computational techniques, ranging from molecular dynamics to the combined use of quantum mechanics and classical mechanics, included in the study have allowed the characterisation of the catalytic state of 9DB1. Using these approaches, the researchers have achieved the first atomic description of the reaction mechanism of a DNAzyme and have characterised the most important interaction in the catalysis and in the transition state of the reaction. 

They have experimentally synthesised in vitro variants of 9DB1 to confirm the mechanism that was predicted through the computational approach. The reaction mechanism used by the DNAzyme resembles that of polymerases, which use two divalent cations. 

Finally, the scientists have analysed the differences and similarities between the catalytic capacity of DNA, RNA and polymerases. Such atomic information is expected to lead to the design of more efficient DNAzymes.

The study has been funded by the Ministry of Science, Innovation and Universities, the Catalan Government, the Spanish National Bioinformatics Institute, the European Research Council (ERC), the Horizon 2020 Programme of the European Union, and the European Regional Development Fund (ERDF).

 

Reference article:

Juan Aranda, Montserrat Terrazas, Hansel Gómez, Núria Villegas and Modesto Orozco

An artificial DNAzyme RNA ligase shows a reaction mechanism resembling that of cellular polymerases

Nature Catalysis (2019) DOI: 10.1038/s41929-019-0290-y

 

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).